The omega-3 index, the percentage of EPA plus DHA in erythrocytes (measured by standardised analysis), represents a human body’s status in EPA and DHA. An omega-3 index is measured in many laboratories around the world; however, even small differences in analytical methods entail large differences in results. Nevertheless, results are frequently related to the target range of $8–11\%$, defined for the original and scientifically validated method (HS-Omegâ-3 Index®), raising ethical issues, and calling for standardisation. No human subject has an omega-3 index $<2\%$, indicating a vital minimum. Thus, the absence of EPA and DHA cannot be tested against presence. Moreover, clinical events correlate with levels, less with the dose of EPA and DHA, and the bioavailability of EPA and DHA varies inter-individually. Therefore, the effects of EPA and DHA are difficult to demonstrate using typical drug trial methods. Recent epidemiologic data further support the relevance of the omega-3 index in the cardiovascular field, since total mortality, cardiovascular mortality, cardiovascular events such as myocardial infarction or stroke, or blood pressure all correlate inversely with the omega-3 index. The omega-3 index directly correlates with complex brain functions. Compiling recent data supports the target range for the omega-3 index of $8–11\%$ in pregnancy. Many other potential applications have emerged. Some, but not all health issues mentioned have already been demonstrated to be improved by increasing intake of EPA and DHA. Increasing the omega-3 index into the target range of $8–11\%$ with individualised doses of toxin-free sources for EPA and DHA is tolerable and safe.

**n-3 Fatty acids: EPA: DHA**

The omega-3 index was defined as the percentage of EPA and DHA in a total of twenty-six specific fatty acids in erythrocytes in 2004\(^1\). An integral part of the definition was the highly standardised analytical procedure\(^1,2\). As discussed in more detail elsewhere, every step of the analytical method impacts substantially on the result\(^2\). Moreover, parameters such as time and vigour of shaking the sample during lipid extraction, or time and agent used for transmethylation impacted on results\(^2\). Nevertheless, it was possible to standardise the analytical method in three geographically distinct laboratories, with regular proficiency testing demonstrating the fruitfulness of the efforts\(^2\).

Many laboratories around the world have their own methods to analyse erythrocyte fatty acids, and some are using these methods to produce results they call omega-3 index. However, quantitatively, the results differ from the results obtained with the standardised method, i.e. are either higher or lower\(^2\). This is problematic if the target range of $8–11\%$ of the standardised method is used as a reference. This can lead to over-supplementation (overshooting the target range, potential risk of bleeding) or under-supplementation (not reaching the target value, increased risk for total mortality and other untoward clinical events)\(^3–7\). Either way, non-
standardised measurements create serious ethical issues; standardising the omega-3 index methodology is needed. Currently, the standardised analytical method can be identified by the trademark HS-Omega-3 Index®. As with all other laboratory parameters, standardisation of the omega-3 index is one of the prerequisites for this parameter entering clinical medicine.

The present review of scientific publications highlights developments in the past two years.

Omega-3 index and human life

Using the standardised method to analyse erythrocytes, and more than 20,000 samples from Omegamatrix clinical routine determinations, no sample was found with an omega-3 index <2% (Fig. 1). The same was true for tens of thousands of samples from the Omegamatrix two sister laboratories called Omegaquant in Sioux Falls, SD, USA and Seoul, South Korea (data not shown). Thus, human life without a defined minimum of EPA and DHA in erythrocytes remains to be found, i.e. minimum levels of EPA and DHA seem to be needed for human life. This puts the discussion, as to whether EPA and DHA can be considered drugs, to rest. Life without drugs is possible, whereas life without EPA and DHA is not.

How the human body maintains these minimum levels is unclear. Individuals, such as vegans or vegetarians, ingest minimal amounts EPA and DHA (e.g. in one study the mean was 1.5 (sd 3.5)mg/d EPA and 2.8 (sd 10.1) mg DHA/d according to dietary recall), yet in these individuals, the mean omega-3 index found was 3.7 (sd 1.0)% (8). In vegans or vegetarians, the omega-3 index did not correlate with the intake of α-linolenic acid (8), which was also true for omnivores in a country, such as Canada, with high intake of α-linoleic containing flaxseed (9). As a general rule, no level is solely controlled by the influx, i.e. amounts going into the pool, but also by other factors, such as distribution volume (pool size), and efflux, i.e. amounts leaving the pool. The pool size for EPA and DHA in human subjects has not been determined, and what factors regulate the catabolism of EPA and DHA have not yet been well defined in quantitative terms. It is not yet clear whether small amounts of α-linolenic acid are metabolised to EPA or DHA, or whether catabolism of EPA and DHA is shut off to maintain a minimum omega-3 index (10,11). Correspondingly, EPA and DHA might be essential because life without a minimum omega-3 index is not possible. Alternatively, this may not be the case if a minimum omega-3 index arises from α-linoleic acid metabolism to EPA and/or DHA. The question of essentiality cannot be resolved by simply analysing the levels of fatty acids, but only by detailed metabolic studies in appropriate populations.

Issues in trial design

Frequently, clinical research organisations are hired to conduct a multi-centre trial. By default, clinical research organisations ask trial participants to ingest their trial medication in the morning, which was also the case in many, but not all large trials with clinical endpoints in the omega-3 field (12,13). Trial medication in such trials frequently was one capsule containing 1 g fat containing 860 mg EPA and DHA (12,13). In many countries, breakfast is a low-fat meal, if eaten at all. Bioavailability of EPA and DHA is minimal with a low-fat meal, since fat absorption requires a number of steps that are activated by a high-fat, but not by a low-fat meal (14,15). In other words, the bioavailability of EPA and DHA was minimised by asking participants to ingest EPA and DHA in the morning.

Moreover, in all trials so far, participants were recruited irrespective of their baseline omega-3 index (12,13). Patients with congestive heart failure with reduced ejection fraction or major depression are characterised by a low omega-3 index, but in many other health issues, such as coronary artery disease, this is not necessarily the case (12,13,16,17). In addition, uptake of EPA and DHA has high inter-individual variability, e.g. by a factor 13 in one trial (18). The consequence of both inhomogeneous baseline levels and high inter-individual variability of uptake was that on-trial levels of EPA and DHA largely overlapped among placebo and verum groups (19). Since clinical events correlate with the levels rather than with the intake of omega-3s, this made it impossible to discern an effect of the intervention with EPA and DHA (12,13). The issues mentioned here are discussed in more detail elsewhere (12,13). In the future, recruitment of trial participants will have to depend on a low baseline omega-3 index (room for improvement needed), and doses of EPA and DHA will have to be individualised, in order to separate the levels in the placebo and verum groups. Positive trial results in populations characterised by a low omega-3 index, such as patients with major depression or congestive heart failure with reduced ejection fraction, support this approach, although the dose was not individualised in the pertinent trials (20,21). Individualising the dose is likely to increase the effect, and thus reduce the sample size, as well as reduce the untoward effects (12). The latter is supported by the results of trials using high doses of EPA and/or DHA, as in the JELIS or REDUCE-It trials (6,7). In both cases, the cost of a positive trial result was a small increase in bleeding episodes (0.1%/year) (6,7).

Unfortunately, perception of the effectiveness of EPA and DHA in clinical medicine is frequently shaped by the results of pertinent Cochrane-Analyses. Cochrane-Analyses include trials based on standardised Cochrane-criteria designed for drug trials. In areas in which EPA and DHA have been tested in randomised controlled trials, Cochrane-Analyses tend to demonstrate no or only small effects (22). This is because Cochrane-criteria do not allow trials with the design issues just discussed to be excluded.

Cardiovascular effects

The magnitude of the potential effects of EPA and DHA can be estimated by considering the results of
epidemiologic studies, e.g. the Framingham study, using the original omega-3 index. With an omega-3 index >6·8 %, total mortality was 65 % of total mortality with an omega-3 index <4·2%\(^3\), reflecting very similar results from earlier studies\(^4,5\). The respective numbers for total CVD (63 %), total CHD (59 %) and total stroke (47 %) were similar\(^3\). Interestingly, simultaneously measured cholesterol levels were no risk for any of the events mentioned\(^3\). The risk for peripheral artery disease was also substantially lower with a higher omega-3 index than with a lower omega-3 index\(^23\). When dietary intake was assessed, associations with the health issues mentioned were substantially smaller\(^24,25,26\). Together with the positive results from large intervention trials, the numbers mentioned support the use of the omega-3 index to maximise the benefit and minimise the risk of EPA and DHA in the prevention of mortality and CVD. In keeping, the American Heart Association has issued scientific advisories recommending EPA and DHA for the secondary prevention of CVD but refrained from mentioning a dose\(^27,28\).

An association between the intake of fish and blood pressure was not found\(^31\). However, the circulating levels of EPA and DHA were inversely related to blood pressure\(^31\). In a representative assessment of the entire population of Liechtenstein, the omega-3 index correlated inversely with blood pressure (both systolic and diastolic), whether assessed over 24 h, during daytime or night, or conventionally in the office. The inverse correlation was independent of age and sex and other confounders such as BMI, smoking status, glycated haemoglobin A1c, educational status, fruit and vegetable consumption, physical activity and others\(^32\). Endothelial function improved in intervention trials, also depending on the omega-3 index\(^33,34\). Meta-analyses of intervention trials demonstrated that EPA and DHA lower blood pressure\(^35\).

### Brain and the omega-3 index

As mentioned, in the Framingham study, an omega-3 index of 6·8 % was associated with a 53 % lower risk for total stroke than an omega-3 index of 4·2%\(^3\). In the Reduce-It trial, in the verum group, stroke occurred in ninety-eight patients, whereas it occurred in 134 patients in the placebo group, a 28 % reduction (hazard ratio 0·72, 95 % CI 55, 0·93, \(P = 0·01\))\(^7\). Therefore, n-3 fatty acids must be considered a powerful possibility for preventing the stroke, a catastrophic event for brain structure and thus brain function.

In an epidemiologic study in children with a mean age of 4, the omega-3 index correlated with complex brain functions, and a low omega-3 index can be found in these patients\(^18,29,30\). A large intervention trial with approximately 860 mg EPA and DHA daily in patients with congestive heart failure with reduced ejection fraction increased the omega-3 index in the verum group from 4·75 (sd 1·68) to 6·73 (sd 1·93) % after 3 months, whereas it remained constant about 4·77 (sd 1·60) in the placebo group\(^30\). The target range was not reached, but, since omega-3 index levels in the verum group were somewhat separated from omega-3 index levels in the placebo group, the primary endpoint, a combination of total mortality and hospitalisations, was significantly reduced in the verum group\(^23\).

An association between the intake of fish and blood pressure was not found\(^31\). However, the circulating levels of EPA and DHA were inversely related to blood pressure\(^31\). In a representative assessment of the entire population of Liechtenstein, the omega-3 index correlated inversely with blood pressure (both systolic and diastolic), whether assessed over 24 h, during daytime or night, or conventionally in the office. The inverse correlation was independent of age and sex and other confounders such as BMI, smoking status, glycated haemoglobin A1c, educational status, fruit and vegetable consumption, physical activity and others\(^32\). Endothelial function improved in intervention trials, also depending on the omega-3 index\(^33,34\). Meta-analyses of intervention trials demonstrated that EPA and DHA lower blood pressure\(^35\).

### Pregnancy and lactation

Premature birth before week 34 of pregnancy is more likely with low levels than with high levels of EPA and DHA in plasma or erythrocytes, with the risk for preterm birth correlating inversely with those levels\(^43,44\). Another publication found post-partum depression to strongly depend on...
the omega-3 index, i.e. with a higher omega-3 index, post-partum depression was much less likely than with a lower omega-3 index. Unfortunately, however, the findings are not directly comparable to the results obtained with the original omega-3 index, since different analytical procedures were used.

In 2018, a large Cochrane Meta-Analysis clearly found premature birth to be reduced both before weeks 34 and 37, gestational age to be prolonged by 1-67 days (95 % CI 0-95, 2-39), based on forty-one randomised controlled trials in 12 517 pregnant women, a lower incidence of low birth weight 15-6 v. 14 %; relative risk 0-90 (95 % CI 0-82, 0-99), based on fifteen randomised controlled trials in 8 449 pregnant women, and relative risk for perinatal death of the child to be 0-75 (95 % CI 0-54, 1-03), based on ten randomised controlled trials in 7 416 pregnant women, and more benefits for mother and child (all comparisons relative to placebo or control) [46]. In the practical conclusion, the authors mentioned: A universal supplementation can make sense, although, with better knowledge, it should be aimed for women benefitting the most [46].

Already in 2016, the omega-3 index had been assessed in an almost representative manner in pregnant and lactating women in Germany and was found to be between 2-49 and 11-10 % regardless of timepoint (pregnancy v. lactation) and whether the woman supplemented EPA and DHA [47]. Taken together, in this author’s opinion, the data to date make it necessary to determine the omega-3 index before or early in pregnancy, later in pregnancy and in lactation to make a targeted supplementation feasible, with a target range of 8-11 % for the omega-3 index.

**Omega-3 index in sports medicine**

In 2014, we had observed that 106 German world class athletes had a mean omega-3 index of 4-97 (sd 1-19) %, with only one athlete in the target range [48]. More recently, similar data were found in 404 US national division I college football athletes with a mean omega-3 index of 4-4 (sd 0-8) %, again only one athlete in the target range [49]. Interestingly, the more energy was burned throughout the season, the lower the omega-3 index became [50]. This has important implications for athletes, since a low omega-3 index predisposes to delayed-onset muscle soreness, and increasing the omega-3 index results in less creatine kinase release from muscle, less inflammatory reaction (measured as muscle swelling and pro-inflammatory cytokines in plasma) and less loss of function [51,52]. Joint pain was reduced with a higher omega-3 index, at least in dogs [53]. Joint stability, e.g. in the case of the shoulder rotator cuff, was higher with a higher omega-3 index [54]. In an intervention trial, it had been demonstrated that brain damage, assessed as neurofilament light (the pertinent biomarker), can be reduced with high doses of EPA and DHA in professional players of American football [55]. Jointly, these findings point towards higher membrane stability with a higher omega-3 index. Together with the aspects of cognition that have been improved by EPA and DHA in intervention trials in athletes, such as reaction time and efficiency [56], current data indicate that an omega-3 index in the target range may be an important asset for the athlete. This is supported by the fact that athletes are at an increased risk for major depression, suicide and sudden cardiac death, all in keeping with a low omega-3 index, and all seriously impacting on an athlete’s life [46].

**Other recent findings**

Conventionally, SFA are considered as a homogenous group with an ominous effect on life expectancy. With the determination of the original omega-3 index comes the measurement of six individual SFA in erythrocytes [11]. It was thus determined that palmitic acid (C16:0) was associated with increased total mortality in a 10-year epidemiologic study of 3259 participants, while the other erythrocyte SFA investigated (C14:0, C18:0, C20:0, C22:0, C24:0) had no association with total mortality [57]. In a meta-analysis, higher levels of palmitic acid were associated with a higher risk for developing type 2 diabetes [58]. In a single study, this was also true for gestational diabetes [59]. Cell membrane levels of palmitic acid are partly derived from ingested palmitic acid, and partly produced endogenously, e.g. in reaction to energetic surplus [60]. Together with other findings of individual structure, metabolism, biologic effects and impacts on life expectancy, our findings question the conventional group-wise nomenclature of fatty acids (e.g. SFA, PUFA and others), as well as the conventional recommendation to avoid all SFA. Whether high levels of palmitic acid might be a biomarker for metabolically untoward body fat, such as excess hepatic fat, remains to be investigated, which is also true for the potential effects of actively reducing levels of palmitic acid.

The findings just discussed were mirrored in an epidemiologic study in children with a median age of 11 years, with palmitic acid correlating positively with waist circumference, TAG, fasting insulin and fatty liver index, against the background of a low omega-3 index (4-7 %) [61]. Interestingly, the levels of arachidonic acid correlated inversely with the parameters mentioned [61]. According to a recent meta-analysis, high levels of EPA and DHA in plasma or erythrocytes were associated with a low risk for the metabolic syndrome [62]. Thus, the omega-3 index makes it possible to investigate the relations between metabolism and non-ω-3 fatty acids in more detail.

In patients with chronic fatigue syndrome/myalgic encephalomyelitis, a low mean omega-3 index was found [63]. Chronic fatigue syndrome/myalgic encephalomyelitis is a debilitating chronic medical condition without a known aetiology, so clinically established diagnostic test and no effective pharmacologic treatment [63]. Our findings add chronic fatigue syndrome/myalgic encephalomyelitis to the list of chronic inflammatory diseases where EPA and DHA should be tested in intervention trials for potential therapeutic value [63].

Some recent intervention trials with EPA and DHA had neutral results. In one trial, it became clear by measuring the omega-3 index that this was due to participants’
non-compliance. In another trial, effects on cognitive parameters were smaller than expected within the 16-week trial period, demonstrating the difficulties of such trials.

Conclusion

In the years 2018 and 2019, a perspective on EPA and DHA levels has proven useful to generate new knowledge on fatty acids, such as there is no human life with an omega-3 index ≤ 2% in erythrocytes. Deficits in EPA and DHA, i.e. an omega-3 index below the target range of 8–11%, have been found in many countries and populations. A deficit in EPA and DHA is associated with increased total mortality, fatal and non-fatal cardiovascular events, stroke, impaired cognition, premature birth, perinatal mortality and other health issues. A deficiency trial. Reducing a deficit in EPA and DHA prolongs life, and reduces fatal and non-fatal cardiovascular events, strokes, premature birth, perinatal mortality and other health issues. In a trial, this can only be detected if the levels in the verum group differ sufficiently from the levels in the placebo or control group. Increasing the omega-3 index into the target range of 8–11% with individualised doses of toxin-free sources for EPA and DHA is tolerable and safe.

Financial Support

The present work was not supported by any funding agency or by industry.

Conflict of Interest

C. v. S. operates Omegametrix, a laboratory for fatty acid analyses. In the past 3 years, C. v. S. received honoraria for speaking and consulting from BASF/Pronova, EPAX, Huntsworth Medical, Abbott, DSM, Marine Ingredients and Norsan.

Authorship

The author had sole responsibility for all aspects of preparation of this paper.

References

1. Harris WS & von Schacky C (2004) The omega-3 index: a new risk factor for death from CHD? Prev Med 39, 212–220.
2. Harris WS, von Schacky C & Park Y (2013) Standardizing methods for assessing omega-3 fatty acid status. In The Omega-3 Fatty Acid Deficiency Syndrome, pp. 385–398. [McNamara RK, editor]. Hauppauge, NY: Nova Science Publishers.
3. Harris WS, Timtle NL, Etherton MR et al. (2018) Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: the Framingham Heart Study. J Clin Lipidol 12, 718–727.
4. Kleber ME, Delgado GE, Lorkowski S et al. (2016) Omega-3 fatty acids and mortality in patients referred for coronary angiography – the Ludwigshafen risk and cardiovascular health study. Atherosclerosis 252, 157–181.
5. Harris WS, Luo J, Pottala JV et al. (2017) Red blood cell polyunsaturated fatty acids and mortality in the women’s health initiative study. J Clin Lipidol 11, 250–259.
6. Yokoyama M, Origasa H, Matsuzaki M et al. (2007) Japan EPA lipid intervention study (JELIS) Investigators (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369, 1090–1098.
7. Bhatt DL, Steg PG, Miller M et al. (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380, 11–22.
8. Sarter B, Kelsey KS, Schwartz TA et al. (2015) Blood docosahexaenoic acid and eicosapentaenoic acid in vegans: associations with age and gender and effects of an algal-derived omega-3 fatty acid supplement. Clin Nutr 34, 212–218.
9. Langlois K & Ratnayake WMN (2015) Omega-3 index of Canadian adults. Statistics Canada, Catalogue No. 82–003–X. Health Rep 26, 3–11.
10. Plourde M & Cunnane SC (2007) Extremely limited synthesis of long chain polysaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab 32, 619–634.
11. Metherel AH & Bazinet RP (2019) Updates to the n-3 fatty acid metabolism. Prog Lipid Res 76, 573–584.
12. von Schacky C (2015) Omega-3 fatty acids in cardiovascular disease – an uphill battle. Prostaglandins Leukot Essent Fatty Acids 92, 41–47.
13. Rice HB, Bernasconi A, Maki KC et al. (2016) Conducting omega-3 clinical trials with cardiovascular outcomes: proceedings of a workshop held at ISSFAL 2014. Prostaglandins Leukot Essent Fatty Acids 107, 30–42.
14. Davidson MH, Johnson J, Rooney MW et al. (2012) A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova (®)) compared to Lovaza® in a pharmacokinetic single-dose evaluation study. J Clin Lipidol 6, 573–584.
15. Schuchardt JP & Hahn A (2013) Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 89, 1–8.
16. Berliner D, Mattern S, Wellige M et al. (2019) The omega-3 index in patients with heart failure: a prospective cohort study. Prostaglandins Leukot Essent Fatty Acids 140, 34–41.
17. Baghai TC, Varallo-Bedarida G, Born C et al. (2011) Major depression is associated with cardiovascular risk factors and low omega-3 index. J Clin Psychiatry 72, 1242–1247.
18. Köhler A, Bittner D, Löw A et al. (2014) Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index. Br J Nutr 104, 729–736.
19. Muhlhausler BS, Gibson RA, Yelland LN et al. (2014) Heterogeneity in cord blood DHA concentration: towards an explanation. Prostaglandins Leukot Essent Fatty Acids 91, 135–140.
20. Grosso G, Pajak A, Marventano S et al. (2014) Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS ONE 9, e96905.

21. Tavazzi L, Maggioni AP, Marchioli R et al. (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1223–1230.

22. Abdelhamid AS, Brown TJ, Brainard JS et al. (2018) Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 11, CD003177.

23. Ramirez JL, Zahnier GJ, Spaulding KA et al. (2019) Peripheral artery disease is associated with a deficiency of erythrocyte membrane n-3 polyunsaturated fatty acids. Lipids 54, 211–229.

24. Micha R, Peñalvo JL, Cudhea F et al. (2017) Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. JAMA 317, 912–924.

25. Chowdhury R, Warnakula S, Kunutsor S et al. (2014) Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 160, 398–406.

26. Chowdhury R, Stevens S, Gorman D et al. (2012) Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. Br Med J 345, e6698.

27. Siscovick DS, Barringer TA, Fretts AM et al. (2017) Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American heart association. Circulation 135, e867–e884.

28. Rimm EB, Appel LJ, Chiuee SE et al. (2018) Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association. Circulation 138, e35–e47.

29. Mozaffarian D, Lemaitre RN, King IB et al. (2011) Circulating long-chain n-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann Intern Med 155, 160–170.

30. Harris WS, Masson S, Barlera S et al. (2016) Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico – Heart Failure trial. Nutr Res 36, 989–994.

31. Yang B, Shi MQ, Li ZH et al. (2016) Fish, long-chain n-3 PUFA and incidence of elevated blood pressure: a meta-analysis of prospective cohort studies. Nutrients 8, pii: E58.

32. Filipovic MG, Aeschbacher S, Reiner MF et al. (2018) Whole blood omega-3 fatty acid concentrations are inversely associated with blood pressure in young, healthy adults. J Hypertens 36, 1548–1554.

33. Skulas-Ray AC, Kris-Etherton PM, Harris WS et al. (2011) Dose response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy people with moderate hypertriglyceridemia. Am J Clin Nutr 93, 243–252.

34. Wang Q, Liang X, Wang L et al. (2012) Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis 221, 536–543.

35. Miller PE, Van Elswyk M & Alexander DD (2014) Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens 27, 885–896.

36. Adjepong M, Yakah W, Harris WS et al. (2018) Whole blood n-3 fatty acids are associated with executive function in 2–6-year-old Northern Ghanaian children. J Nutr Biochem 57, 287–293.

37. Dretsch MN, Johnston D, Bradley RS et al. (2014) Effects of omega-3 fatty acid supplementation on neurocognitive functioning and mood in deployed U.S. Soldiers: a pilot study. Mil Med 179, 396–403.

38. Tan ZS, Harris WS, Beiser AS et al. (2012) Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology 78, 658–664.

39. Lukasehek K, von Schacky C, Kruse J et al. (2016) Cognitive impairment is associated with low omega-3 Index in the elderly. Results from the KORA-Age study. Dementia Geriatr Cogn Dis 42, 236–245.

40. Bigornia SJ, Scott TM, Harris WS et al. (2018) Prospective associations of erythrocyte composition and dietary intake of n-3 and n-6 PUFA with measures of cognitive function. Nutrients 10, 1253.

41. Witte AV, Kerti L, Hermannstädter HM et al. (2014) Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb Cortex 24, 3059–3068.

42. Külzow N, Witte AV, Kerti L et al. (2016) Impact of omega-3 fatty acid supplementation on memory functions in healthy older adults. J Alzheimers Dis 51, 713–725.

43. Olsen SF, Hallдоровsson TI, Thorne-Lyman AL et al. (2018) Plasma concentrations of long chain N-3 fatty acids in early and mid-pregnancy and risk of early preterm birth. EBioMedicine 35, 325–333. Correction in Olsen SF, Hallдоровsson TI, Thorne-Lyman AL et al. (2020) Corrigendum to ‘Plasma concentrations of long chain N-3 fatty acids in early and mid-pregnancy and risk of early preterm birth. EBioMedicine. 51 102619.

44. Hoge A, Donneau AF, Dardenne N et al. (2020) Impact of erythrocyte long-chain omega-3 polyunsaturated fatty acid levels in early pregnancy on birth outcomes: findings from a Belgian cohort study. J Perinatol 40, 488–496.

45. Hoge A, Tabar V, Donneau AF et al. (2019) Imbalance between omega-6 and omega-3 polyunsaturated fatty acids in early pregnancy is predictive of postpartum depression in a Belgian cohort. Nutrients 11, pii: E876.

46. Middleton P, Gomersall JC, Gould JF et al. (2018) Omega-3 fatty acid addition during pregnancy. JAMA 319, 541–543.

47. Davinelli S, Corbi G, Righetti S et al. (2020) Relationship between distance run per week, omega-3 index, and arachidonic acid (AA)/eicosapentaenoic acid (EPA) ratio: an observational retrospective study in non-elite runners. Front Physiol 10, 487.

48. Kim J & Lee J (2014) A review of nutritional intervention on delayed onset muscle soreness. Part I. J Exerc Rehabil 10, 349–356.
52. Ochi E & Tsuchiya Y (2018) Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in muscle damage and function. *Nutrients* **10**, pii: E552.

53. Burri L, Wyse C, Gray SR *et al.* (2018) Effects of dietary supplementation with krill meal on serum pro-inflammatory markers after the Iditarod sled dog race. *Res Vet Sci* **121**, 18–22.

54. Hudek R, von Schacky C, Passow A *et al.* (2019) Degenerative rotator cuff tears are associated with a low omega-3 index. *Prostaglandins Leukot Essent Fatty Acids* **148**, 35–40.

55. Oliver JM, Jones MT, Kirk KM *et al.* (2016) Effect of docosahexaenoic acid on a biomarker of head trauma in American football. *Med Sci Sports Exerc* **48**, 974–982.

56. Guzmán JF, Esteve H, Pablos C *et al.* (2011) DHA-rich fish oil improves complex reaction time in female elite soccer players. *J Sports Sci Med* **10**, 301–335.

57. Kleber ME, Delgado GE, Dawczynski C *et al.* (2016) Saturated fatty acids and mortality in patients referred for coronary angiography – the Ludwigshafen risk and cardiovascular health study. *J Clin Lipidol* **12**, 455–463.

58. Huang L, Lin JS, Aris IM *et al.* (2019) Circulating saturated fatty acids and incident type 2 diabetes: a systematic review and meta-analysis. *Nutrients* **11**, 5.

59. Zhu Y, Tsai MY, Sun Q *et al.* (2018) A prospective and longitudinal study of plasma phospholipid saturated fatty acid profile in relation to cardiometabolic biomarkers and the risk of gestational diabetes. *Am J Clin Nutr* **107**, 1017–1026.

60. Carta G, Murru E, Banni S *et al.* (2017) Palmitic acid: physiological role, metabolism and nutritional implications. *Front Physiol* **8**, 902.

61. Bonafini S, Tagetti A, Gaudino R *et al.* (2019) Individual fatty acids in erythrocyte membranes are associated with several features of the metabolic syndrome in obese children. *Eur J Nutr* **58**, 731–742.

62. Jang H & Park K (2020) Omega-3 and omega-6 polyunsaturated fatty acids and metabolic syndrome: a systematic review and meta-analysis. *Clin Nutr* **39**, 767–773.

63. Castro-Marreroa J, Zaragozáa MC, Domingo JC *et al.* (2018) Low omega-3 index and polyunsaturated fatty acid status in patients with chronic fatigue syndrome/myalgic encephalomyelitis: myth or reality? *Prostaglandins Leukot Essent Fatty Acids* **139**, 20–24.

64. van der Wurff I, von Schacky C, Bergeland T *et al.* (2019) Effect of 1 year krill oil supplementation on cognitive achievement of Dutch adolescents: a double-blind randomized controlled trial. *Nutrients* **11**, pii: E1230.

65. Schättin A, Baier C, Mai D *et al.* (2019) Effects of exergame training combined with omega-3 fatty acids on the elderly brain: a randomized double-blind placebo-controlled trial. *BMC Geriatr* **19**, 81.

66. von Schacky C (2019) Verwirrung um die Wirkung von omega-3 Fettsäuren. Betrachtung von Studiendaten unter Berücksichtigung des omega-3 Index. [Confusion about the effects of omega-3 fatty acids: contemplation of study data taking the omega-3 Index into consideration]. *Internist (Berl)* **60**, 1319–1327.